Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Conditions
Interventions
CB-839
Cabozantinib
+1 more
Locations
133
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic Cancer Center
Phoenix, Arizona, United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
Stanford Cancer Center
Palo Alto, California, United States
Salinas Valley Memorial Healthcare System
Salinas, California, United States
Start Date
April 24, 2018
Primary Completion Date
August 31, 2020
Completion Date
July 16, 2021
Last Updated
March 20, 2023
NCT05969860
NCT04693377
NCT06500455
NCT06863311
NCT07123090
NCT06391099
Lead Sponsor
Calithera Biosciences, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions